Pfizer GDF15 Monoclonal Antibody Ponsegromab Injection Applied for Clinical Application
On May 10, CDE's official website showed that Pfizer's clinical trial application for Ponsegromab injection was accepted. This is the first GDF15 monoclonal antibody to be declared for clinical application in China, which can be used for the treatment of cancer cachexia, solid tumors, anorexia, heart failure, etc.
Ponsegromab is currently mainly developed for the treatment of cancer cachexia (cancer cachexia). This is a secondary reaction characterized by systemic metabolic disorders mainly caused by tumor cell products and cytokines released by the body, manifested as loss of appetite, weight loss, anemia, weakness, and exhaustion. About 20% of cancer patients' deaths are related to cancer cachexia.
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
2026-07-26
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
How Can Investors Benefit from Pfizer's Dividend Yield for a Monthly Income?
-
Pfizer's Revenue Forecast Disappoints, Stock Plummets: A Closer Look at the Challenges Ahead
-
Pfizer's Angela Hwang Departs as Company Completes Seagen Acquisition and Establishes New Oncology Division
-
2023 Senior Management Personnel Changes of Multinational Pharmaceutical Companies in China, what's behind it? - III
-
Milestone Approvals in Sickle Cell Disease (SCD): FDA Approves Two Therapies before Pfizer's GBT601 Disclosure
-
Pfizer's Strategic Shift in China's Pneumococcal Vaccine Market
-
Pfizer Receives Conditional Approval for Tislelizumab in the Treatment of Relapsed or Refractory Extranodal NK/T-cell Lymphoma (ENKTL)
-
Pfizer: In 2023, COVID-19's product revenue will decline significantly
-
25 million with one injection?! The record for 'the world's most expensive drug' is still controversial...
-
Pfizer's paxlovid reduces the risk of COVID-19 by 26%
Recommend Reading
-
Maintenance Concentration Leads to Cost Decline; April PP Market Experiences Volatile Performance
-
Upstream Decline & Lackluster Trading Activity: April PC Prices Fall from High Levels
-
Costs Decline, Consumption Weakens—ABS Prices Drop Sharply in April
-
In April, the Shandong Asphalt Market First Declined Then Rose, What Will Happen Next?
-
April Benzene Market Trend Summary (April 1-30, 2026) in China